Stock analysis searches answered, part 14 of 43

Nuwellis, inc. bullish and bearish analyst opinions

This section ties “Nuwellis, inc. bullish and bearish analyst opinions” to Nuwellis, Inc. (ticker NUWE), SEC Central Index Key 1506492, an EDGAR registrant classified as “Electromedical & Electrotherapeutic Apparatus” and organised in DE, formerly known as CHF Solutions, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Financial trend for Nuwellis, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $8.54 million (2022-12-31) to $8.27 million (2025-12-31), a change of -3.2%; net income (loss) went from -$14.53 million (2022-12-31) to -$17.52 million (2025-12-31), a change of -20.6%; total assets went from $24.67 million (2022-12-31) to $6.12 million (2025-12-31), a change of -75.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1506492, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Nuwellis, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Nuwellis, Inc. (CIK 1506492) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-11. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 241 8-K or 6-K reports in Nuwellis, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-03 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, Nuwellis, Inc. most often filed 4 (265), 8-K (241), CORRESP (44), 10-Q (41). A selection from 2026-08-14 to 2026-09-18:

The full record for CIK 1506492 is on the EDGAR company page; the latest 10-K there is dated 2026-03-11 and the oldest filing in the recent index dates from 2013-01-28. Insider trades for Nuwellis, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Olema pharmaceuticals, inc. bullish and bearish analyst opinions

This section ties “Olema pharmaceuticals, inc. bullish and bearish analyst opinions” to Olema Pharmaceuticals, Inc. (ticker OLMA), SEC Central Index Key 1750284, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D/A dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-16 by Olema Pharmaceuticals, Inc. (CIK 1750284) — source document:

Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (formerly known as OP-1250), is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), breast cancer. In pre-clinical models, palazestrant binds and completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer.

Financial trend for Olema Pharmaceuticals, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$104.79 million (2022-12-31) to -$162.45 million (2025-12-31), a change of -55.0%; total assets went from $215.65 million (2022-12-31) to $533.43 million (2025-12-31), a change of +147.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1750284, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Olema Pharmaceuticals, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Olema Pharmaceuticals, Inc. (CIK 1750284) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 65 8-K or 6-K reports in Olema Pharmaceuticals, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-23 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1750284 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2018-08-27. Insider trades for Olema Pharmaceuticals, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Onfolio holdings, inc. bullish and bearish analyst opinions

This section ties “Onfolio holdings, inc. bullish and bearish analyst opinions” to Onfolio Holdings, Inc (ticker ONFO, ONFOP, ONFOW), SEC Central Index Key 1825452, an EDGAR registrant classified as “Services-Computer Processing & Data Preparation” and organised in DE, formerly known as Onfolio Holdings Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a S-1 dated 2026-10-23. Nothing here is a recommendation to trade the security.

Financial trend for Onfolio Holdings, Inc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.22 million (2022-12-31) to $10.73 million (2025-12-31), a change of +383.4%; net income (loss) went from -$4.23 million (2022-12-31) to -$2.59 million (2025-12-31), a change of +38.9%; total assets went from $15.78 million (2022-12-31) to $11.36 million (2025-12-31), a change of -28.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1825452, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Onfolio Holdings, Inc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Onfolio Holdings, Inc (CIK 1825452) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 47 8-K or 6-K reports in Onfolio Holdings, Inc’s recent EDGAR index, the 4 listed here run from 2026-08-27 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1825452 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2020-09-23. Insider trades for Onfolio Holdings, Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Optimumbank holdings, inc. bullish and bearish analyst opinions

This section ties “Optimumbank holdings, inc. bullish and bearish analyst opinions” to OptimumBank Holdings, Inc. (ticker OPHC), SEC Central Index Key 1288855, an EDGAR registrant classified as “National Commercial Banks” and organised in FL. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a EFFECT dated 2026-09-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-26 by OptimumBank Holdings, Inc. (CIK 1288855) — source document:

These statements are not historical facts and include expressions concerning the future that are subject to risks and uncertainties. General OptimumBank Holdings, Inc. is a Florida corporation (the “Company”) formed in 2004 as a bank holding company for OptimumBank (the “Bank”). The Company’s only business is the ownership and operation of the Bank. The Bank is a Florida state-chartered bank established in 2000, with deposits insured by the Federal Deposit Insurance Corporation (“FDIC”). The Bank offers a variety of commercial banking services to individual and corporate customers through its headquarters and two branch offices located in Broward County, and one branch office in Miami Dade County, Florida. The Company is subject to the supervision and regulation of The Board of Governors of the Federal Reserve System (the “Federal Reserve”).

Financial trend for OptimumBank Holdings, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $19.88 million (2022-12-31) to $64.35 million (2025-12-31), a change of +223.7%; net income (loss) went from $4.02 million (2022-12-31) to $16.65 million (2025-12-31), a change of +313.8%; total assets went from $585.22 million (2022-12-31) to $1.11 billion (2025-12-31), a change of +90.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1288855, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 4 periods shown, dashes mark figures OptimumBank Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on OptimumBank Holdings, Inc. (CIK 1288855) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-24, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 166 8-K or 6-K reports in OptimumBank Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-05 to 2026-08-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1288855 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2004-05-11. Insider trades for OptimumBank Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Orangekloud technology inc. bullish and bearish analyst opinions

This section ties “Orangekloud technology inc. bullish and bearish analyst opinions” to ORANGEKLOUD TECHNOLOGY INC. (ticker ORKT), SEC Central Index Key 1979407, an EDGAR registrant classified as “Services-Prepackaged Software” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-22, and this view starts from filings dated on or before 2026-05-08. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-30 by ORANGEKLOUD TECHNOLOGY INC. (CIK 1979407) (passage 2, continuing from the earlier excerpt) — source document:

THE OFFER AND LISTING 69 A. Offer and Listing Details. 69 B. Plan of Distribution. 69 C. Markets. 69 D. Selling Shareholders. 69 E. Dilution. 69 F. Expenses of the Issue. 69 2 ITEM 10. ADDITIONAL INFORMATION 69 A. Share Capital. 69 B. Memorandum and Articles of Association. 69 C. Material Contracts. 73 D. Exchange controls. 73 E. Taxation. 73 F. Dividends and paying agents. 79 G. Statement by experts. 79 H. Documents on display. 80 I. Subsidiary Information 80 ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK 80 ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 80 PART II 81 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 81 ITEM 14.

Financial trend for ORANGEKLOUD TECHNOLOGY INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 7,152,092 SGD (2022-12-31) to 5,682,839 SGD (2025-12-31), a change of -20.5%; net income (loss) went from 1,987,887 SGD (2022-12-31) to -4,471,234 SGD (2025-12-31), a change of -324.9%; total assets went from 4,224,139 SGD (2023-12-31) to 11,850,279 SGD (2025-12-31), a change of +180.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1979407, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures ORANGEKLOUD TECHNOLOGY INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ORANGEKLOUD TECHNOLOGY INC. (CIK 1979407) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 27 8-K or 6-K reports in ORANGEKLOUD TECHNOLOGY INC.’s recent EDGAR index, the 4 listed here run from 2026-02-02 to 2026-03-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1979407 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2023-07-06. One example from this record is the S-8 filed 2026-06-10 (document). Insider trades for ORANGEKLOUD TECHNOLOGY INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Oxley bridge acquisition limited bullish and bearish analyst opinions

This section ties “Oxley bridge acquisition limited bullish and bearish analyst opinions” to Oxley Bridge Acquisition Ltd (ticker OBA, OBAWU, OBAWW), SEC Central Index Key 2034313, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-05, and this view starts from filings dated on or before 2025-08-12. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by Oxley Bridge Acquisition Ltd (CIK 2034313) (passage 2, continuing from the earlier excerpt) — source document:

As of the date of this Report, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering, and (iii) searching for and consummating a Business Combination; we have not selected any specific Business Combination target. We have generated no operating revenues to date, and we do not expect that we will generate operating revenues until we consummate our initial Business Combination. Initial Public Offering Our IPO Registration Statement became effective on June 24, 2025. On June 26, 2025, we consummated our Initial Public Offering of 25,300,000 Units, including 3,300,000 Option Units issued pursuant to the full exercise of the Over-Allotment Option. Each Unit consists of one Public Share and one-half of one Public Warrant, with each whole Public Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share.

Financial trend for Oxley Bridge Acquisition Ltd from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $2.43 million (2025-09-30) to $2.16 million (2026-06-30), a change of -11.2%; total assets went from $257.02 million (2025-09-30) to $263.66 million (2026-06-30), a change of +2.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2034313, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Oxley Bridge Acquisition Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Oxley Bridge Acquisition Ltd (CIK 2034313) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Oxley Bridge Acquisition Ltd — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2025-06-25.

Current reports. Of the 6 8-K or 6-K reports in Oxley Bridge Acquisition Ltd’s recent EDGAR index, the 2 listed here run from 2025-06-26 to 2025-07-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2034313 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2024-10-09. One example from this record is the NT 10-Q filed 2026-05-18 (document). Insider trades for Oxley Bridge Acquisition Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pangaea logistics solutions, ltd. bullish and bearish analyst opinions

This section ties “Pangaea logistics solutions, ltd. bullish and bearish analyst opinions” to Pangaea Logistics Solutions Ltd. (ticker PANL), SEC Central Index Key 1606909, an EDGAR registrant classified as “Deep Sea Foreign Transportation of Freight” and organised in Bermuda, formerly known as Quartet Holdco Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-10. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-16 by Pangaea Logistics Solutions Ltd. (CIK 1606909) — source document:

Pangaea Logistics Solutions Ltd. and its subsidiaries collectively, Pangaea or the Company, provide seaborne drybulk logistics and transportation services as well as terminal and stevedoring services. Pangaea utilizes its logistics expertise to service a broad base of industrial customers who require the transportation of a wide variety of drybulk cargoes, including grains, coal, iron ore, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite and limestone. The Company addresses the logistics needs of its customers by undertaking a comprehensive set of services and activities, including cargo loading, cargo discharge, port and terminal operations, vessel chartering, voyage planning, and vessel technical management. Available Information Our Internet website address is www.pangaeals.com.

Financial trend for Pangaea Logistics Solutions Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $79.49 million (2022-12-31) to $19.37 million (2025-12-31), a change of -75.6%; total assets went from $748.24 million (2022-12-31) to $928.10 million (2025-12-31), a change of +24.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1606909, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Pangaea Logistics Solutions Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Pangaea Logistics Solutions Ltd. (CIK 1606909) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 122 8-K or 6-K reports in Pangaea Logistics Solutions Ltd.’s recent EDGAR index, the 4 listed here run from 2026-05-11 to 2026-08-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1606909 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2014-05-01. Insider trades for Pangaea Logistics Solutions Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pba infrastructure limited bullish and bearish analyst opinions

The legal-form ending in “Pba infrastructure limited” is the clue: “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. A company of that kind reports in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), so the place to read its annual report and announcements is that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) — www.hkexnews.hk.

No SEC filer could be matched to “Pba infrastructure limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Pba infrastructure limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “pba” (search terms considered: pba, infrastructure).

EDGAR’s company index has 0 entities whose registered name contains the word “pba”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “pba” 0, “infrastructure” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “infrastructure”: 2021 INFRASTRUCTURE COMPARTMENT (MASTER), A SUB-FUND OF VERTUO (MASTER) S.C.SP SICAV-RAIF (CIK 1989703), 2025 INFRASTRUCTURE COMPARTMENT (MASTER), A SUB-FUND OF VERTUO (MASTER) S.C.SP SICAV-RAIF (CIK 2102517), 361 INFRASTRUCTURE PARTNERS, LLC (CIK 1804253). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “pba” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Perma-pipe international holdings, inc. bullish and bearish analyst opinions

This section ties “Perma-pipe international holdings, inc. bullish and bearish analyst opinions” to Perma-Pipe International Holdings, Inc. (ticker PPIH), SEC Central Index Key 914122, an EDGAR registrant classified as “Industrial & Commercial Fans & Blowers & Air Purifing Equip” and organised in DE, formerly known as MFRI INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-09-09. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-16 by Perma-Pipe International Holdings, Inc. (CIK 914122) — source document:

Perma-Pipe International Holdings, Inc., collectively with its subsidiaries ("PPIH", the "Company", "we", "our" or the "Registrant"), is engaged in the manufacture and sale of products in one reportable segment: Piping Systems. The Company was incorporated in Delaware on October 12, 1993. The Company's common stock is traded on the Nasdaq Global Market and reported under the ticker symbol "PPIH". The Company's fiscal year ends on January 31. Years, results and balances described as 2026, 2025 and 2024 are for the fiscal year ending January 31, 2027 and the fiscal years ended January 31, 2026 and 2025, respectively. PRODUCTS AND SERVICES The Company engineers, designs, manufactures and sells specialty piping systems and leak detection systems.

Financial trend for Perma-Pipe International Holdings, Inc. from annual reports, periods 2023-01-31 to 2026-01-31: net income (loss) went from $5.95 million (2023-01-31) to $17.04 million (2026-01-31), a change of +186.5%; total assets went from $122.97 million (2023-01-31) to $217.49 million (2026-01-31), a change of +76.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 914122, tags Assets, NetIncomeLoss, SalesRevenueNet; 4 periods shown, dashes mark figures Perma-Pipe International Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Perma-Pipe International Holdings, Inc. (CIK 914122) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-09, and the most recent 10-K annual report was filed 2026-04-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 138 8-K or 6-K reports in Perma-Pipe International Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-09 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 914122 is on the EDGAR company page; the latest 10-K there is dated 2026-04-16 and the oldest filing in the recent index dates from 1999-05-03. Insider trades for Perma-Pipe International Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pharmacyte biotech, inc. bullish and bearish analyst opinions

This section ties “Pharmacyte biotech, inc. bullish and bearish analyst opinions” to PharmaCyte Biotech, Inc. (ticker PMCB), SEC Central Index Key 1157075, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in NV, formerly known as NUVILEX, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-07-29 by PharmaCyte Biotech, Inc. (CIK 1157075) — source document:

We are a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed. The current generation of our product candidate is referred to as “CypCaps™.” On November 17, 2023, the Board formed the Strategic Scientific Committee (the “Scientific Committee”), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent consultants are reviewing many of the risks relative to our business. In addition, the Board is reviewing risks associated with our development programs and our relationship with SG Austria Pte.

Financial trend for PharmaCyte Biotech, Inc. from annual reports, periods 2023-04-30 to 2026-04-30: revenue went from $0 (2023-04-30) to $0 (2026-04-30); net income (loss) went from -$4.32 million (2023-04-30) to -$19.42 million (2026-04-30), a change of -350.1%; total assets went from $73.28 million (2023-04-30) to $46.75 million (2026-04-30), a change of -36.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1157075, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures PharmaCyte Biotech, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PharmaCyte Biotech, Inc. (CIK 1157075) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2022-07-11, and the most recent 10-K annual report was filed 2026-07-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 104 8-K or 6-K reports in PharmaCyte Biotech, Inc.’s recent EDGAR index, the 4 listed here run from 2025-10-31 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1157075 is on the EDGAR company page; the latest 10-K there is dated 2026-07-29 and the oldest filing in the recent index dates from 2001-08-20. Insider trades for PharmaCyte Biotech, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Picocela inc. bullish and bearish analyst opinions

This section ties “Picocela inc. bullish and bearish analyst opinions” to PicoCELA Inc. (ticker PCLA), SEC Central Index Key 2018462, an EDGAR registrant classified as “Electric Lighting & Wiring Equipment” and organised in Japan. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-02-13 by PicoCELA Inc. (CIK 2018462) — source document:

All representations of share amounts issued and outstanding prior to October 24, 2024 under this heading do not reflect the to a 60-for-1 share split, which took effect on October 24, 2024. All representations of share amounts issued and outstanding prior to January 26, 2026 under this heading do not reflect the 1-for-30 reverse share split which took effect on January 26, 2026. PicoCELA was incorporated in Tokyo, Japan in 2008 as a joint-stock corporation ( kabushiki kaisha ) with limited liability. As of the date of this annual report, the Company does not have any subsidiaries. On July 5, 2024, we converted all the preferred share then issued and outstanding to Common Shares, and, on July 17, 2024, all classes of preferred shares were eliminated from our authorized share capital.

Financial trend for PicoCELA Inc. from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from 682,121,000 JPY (2022-09-30) to 544,690,000 JPY (2025-09-30), a change of -20.1%; net income (loss) went from -5,180,000 JPY (2022-09-30) to -626,312,000 JPY (2025-09-30), a change of -11991.0%; total assets went from 1,149,212,000 JPY (2023-09-30) to 1,087,166,000 JPY (2025-09-30), a change of -5.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2018462, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures PicoCELA Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PicoCELA Inc. (CIK 2018462) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 22 8-K or 6-K reports in PicoCELA Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-10-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2018462 is on the EDGAR company page; the latest 20-F there is dated 2026-02-13 and the oldest filing in the recent index dates from 2024-06-13. Insider trades for PicoCELA Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Polypid ltd. bullish and bearish analyst opinions

This section ties “Polypid ltd. bullish and bearish analyst opinions” to PolyPid Ltd. (ticker PYPD), SEC Central Index Key 1611842, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in Israel. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-01. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-02-25 by PolyPid Ltd. (CIK 1611842) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 83 A. Operating Results 83 B. Liquidity and Capital Resources 88 C. Research and Development, Patents and Licenses, etc. 92 D. Trend Information 92 E. Critical Accounting Estimates 93 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 95 A. Directors and Senior Management 95 B. Compensation 98 C. Board Practices 99 D. Employees 109 E. Share Ownership 109 F. Action to Recover Erroneously Awarded Compensation 109 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 110 A. Major Shareholders 110 B. Related Party Transactions 114 C. Interests of Experts and Counsel 114 ITEM 8. FINANCIAL INFORMATION 115 A. Consolidated Statements and Other Financial Information 115 B. Significant Changes 115 ITEM 9.

Financial trend for PolyPid Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$39.56 million (2022-12-31) to -$34.17 million (2025-12-31), a change of +13.6%; total assets went from $25.97 million (2022-12-31) to $22.31 million (2025-12-31), a change of -14.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1611842, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures PolyPid Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PolyPid Ltd. (CIK 1611842) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 117 8-K or 6-K reports in PolyPid Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-12 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1611842 is on the EDGAR company page; the latest 20-F there is dated 2026-02-25 and the oldest filing in the recent index dates from 2014-07-08. Insider trades for PolyPid Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Prairie provident resources inc. bullish and bearish analyst opinions

What this search refers to. Prairie Provident Resources Inc. is a Calgary-based oil and gas producer listed on the Toronto Stock Exchange; it files under Canadian rules on SEDAR+. Official source: www.sedarplus.ca.

No SEC filer could be matched to “Prairie provident resources inc. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Prairie provident resources inc.” appears in 2160+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “prairie” (search terms considered: prairie, provident, resources).

A broader EDGAR full-text search for the shorter phrase “Prairie provident resources” finds 2180+ filing documents; among the top 100, the filers mentioning it most are GOLDMAN SACHS TRUST (CIK 0000822977) (31); JNL SERIES TRUST (CIK 0000933691) (28); Goldman Sachs BDC, Inc. (GSBD) (CIK 0001572694) (25). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Prairie provident resources inc.”, filings range from 2016-11-03 to 2026-08-26. The filers whose documents mention it most often are GOLDMAN SACHS TRUST (CIK 0000822977) (31 hits); Goldman Sachs BDC, Inc. (GSBD) (CIK 0001572694) (31 hits); JNL SERIES TRUST (CIK 0000933691) (28 hits); HOTCHKIS & WILEY FUNDS /DE/ (CIK 0001145022) (4 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

Word by word, the number of EDGAR registrant names containing each term of this search is: “prairie” 195, “provident” 147, “resources” 478. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Updated Oct 25, 2026 ET

Promis neurosciences, inc. bullish and bearish analyst opinions

This section ties “Promis neurosciences, inc. bullish and bearish analyst opinions” to ProMIS Neurosciences Inc. (ticker PMN), SEC Central Index Key 1374339, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Canada (Federal Level), formerly known as AMORFIX LIFE SCIENCES LTD. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-06. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-25 by ProMIS Neurosciences Inc. (CIK 1374339) — source document:

ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer’s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS’ technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence.

Financial trend for ProMIS Neurosciences Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$18.06 million (2022-12-31) to -$39.72 million (2025-12-31), a change of -119.9%; total assets went from $6.92 million (2022-12-31) to $9.18 million (2025-12-31), a change of +32.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1374339, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures ProMIS Neurosciences Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ProMIS Neurosciences Inc. (CIK 1374339) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 61 8-K or 6-K reports in ProMIS Neurosciences Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1374339 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2006-08-29. Insider trades for ProMIS Neurosciences Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pt allo bank indonesia tbk bullish and bearish analyst opinions

Read from its name, “Pt allo bank indonesia tbk” is a Indonesia entity — “PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. Its accounts and exchange notices are published through the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK (www.idx.co.id); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Pt allo bank indonesia tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Pt allo bank indonesia tbk” appears in 320+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “allo” (search terms considered: allo, bank, indonesia).

A broader EDGAR full-text search for the shorter phrase “Pt allo bank” finds 320+ filing documents; among the top 100, the filers mentioning it most are JNL SERIES TRUST (CIK 0000933691) (55); Dimensional ETF Trust (CIK 0001816125) (39); John Hancock Exchange-Traded Fund Trust (CIK 0001478482) (2). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “allo” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 100 most relevant full-text hits returned for “Pt allo bank indonesia tbk”, filings range from 2022-08-24 to 2026-09-24. The filers whose documents mention it most often are JNL SERIES TRUST (CIK 0000933691) (55 hits); Dimensional ETF Trust (CIK 0001816125) (39 hits); John Hancock Exchange-Traded Fund Trust (CIK 0001478482) (2 hits); Global Macro Portfolio (CIK 0000918706) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 5 entities whose registered name contains the word “allo”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “allo” 5, “bank” 459, “indonesia” 36. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “allo” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Pt atlas resources tbk bullish and bearish analyst opinions

“PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. The name “Pt atlas resources tbk” therefore points to a company organised in Indonesia, and its official disclosures are on the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK (www.idx.co.id), not on EDGAR.

No SEC filer could be matched to “Pt atlas resources tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Pt atlas resources tbk”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “atlas” (search terms considered: atlas, resources).

Even the shorter phrase “Pt atlas resources” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (atlas, resources) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “atlas” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 181+ entities whose registered name contains the word “atlas”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “atlas” 464, “resources” 478. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “atlas” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Pt bank smbc indonesia tbk bullish and bearish analyst opinions

The legal-form ending in “Pt bank smbc indonesia tbk” is the clue: “PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. A company of that kind reports in Indonesia, so the place to read its annual report and announcements is the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK — www.idx.co.id.

No SEC filer could be matched to “Pt bank smbc indonesia tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Pt bank smbc indonesia tbk” appears in 12 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “smbc” (search terms considered: bank, smbc, indonesia).

A broader EDGAR full-text search for the shorter phrase “Pt bank smbc” finds 12 filing documents; among the top 12, the filers mentioning it most are SUMITOMO MITSUI FINANCIAL GROUP, INC. (SMFG, SMFNF) (CIK 0001022837) (11); PT Sarana Menara Nusantara Tbk (CIK 0002048388) (1). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “smbc” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 12 most relevant full-text hits returned for “Pt bank smbc indonesia tbk”, filings range from 2025-05-30 to 2026-06-26. The filers whose documents mention it most often are SUMITOMO MITSUI FINANCIAL GROUP, INC. (SMFG, SMFNF) (CIK 0001022837) (11 hits); PT Sarana Menara Nusantara Tbk (CIK 0002048388) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 9 entities whose registered name contains the word “smbc”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “bank” 459, “smbc” 9, “indonesia” 36. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “smbc” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Pt goodyear indonesia tbk bullish and bearish analyst opinions

Read from its name, “Pt goodyear indonesia tbk” is a Indonesia entity — “PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. Its accounts and exchange notices are published through the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK (www.idx.co.id); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Pt goodyear indonesia tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Pt goodyear indonesia tbk” appears in 1 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “goodyear” (search terms considered: goodyear, indonesia).

A broader EDGAR full-text search for the shorter phrase “Pt goodyear indonesia” finds 1 filing documents; among the top 1, the filers mentioning it most are Trinseo S.A. (TSE) (CIK 0001519061) (1). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “goodyear” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 1 most relevant full-text hits returned for “Pt goodyear indonesia tbk”, filings range from 2011-06-27 to 2011-06-27. The filers whose documents mention it most often are Trinseo S.A. (TSE) (CIK 0001519061) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 26 entities whose registered name contains the word “goodyear”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “goodyear” 26, “indonesia” 36. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “goodyear” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Pt mizuho leasing indonesia tbk bullish and bearish analyst opinions

“PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. The name “Pt mizuho leasing indonesia tbk” therefore points to a company organised in Indonesia, and its official disclosures are on the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK (www.idx.co.id), not on EDGAR.

No SEC filer could be matched to “Pt mizuho leasing indonesia tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Pt mizuho leasing indonesia tbk”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “mizuho” (search terms considered: mizuho, leasing, indonesia).

Even the shorter phrase “Pt mizuho leasing” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (mizuho, leasing, indonesia) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “mizuho” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

Word by word, the number of EDGAR registrant names containing each term of this search is: “mizuho” 20, “leasing” 484, “indonesia” 36. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “mizuho” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Pyxis tankers inc. bullish and bearish analyst opinions

This section ties “Pyxis tankers inc. bullish and bearish analyst opinions” to Pyxis Tankers Inc. (ticker PXS), SEC Central Index Key 1640043, an EDGAR registrant classified as “Deep Sea Foreign Transportation of Freight” and organised in Marshall Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-04. Nothing here is a recommendation to trade the security.

Financial trend for Pyxis Tankers Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $58.34 million (2022-12-31) to $38.99 million (2025-12-31), a change of -33.2%; net income (loss) went from $13.39 million (2022-12-31) to $1.99 million (2025-12-31), a change of -85.1%; total assets went from $138.98 million (2022-12-31) to $193.41 million (2025-12-31), a change of +39.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1640043, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Pyxis Tankers Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Pyxis Tankers Inc. (CIK 1640043) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-01. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 143 8-K or 6-K reports in Pyxis Tankers Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-10 to 2026-09-04, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 286 recent EDGAR filings, Pyxis Tankers Inc. most often filed 6-K (143), CORRESP (23), 424B3 (18), 20-F (11). A selection from 2026-05-28 to 2026-07-23:

The full record for CIK 1640043 is on the EDGAR company page; the latest 20-F there is dated 2026-04-01 and the oldest filing in the recent index dates from 2015-04-23. Insider trades for Pyxis Tankers Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Radcom ltd. bullish and bearish analyst opinions

This section ties “Radcom ltd. bullish and bearish analyst opinions” to RADCOM LTD (ticker RDCM), SEC Central Index Key 1016838, an EDGAR registrant classified as “Computer Peripheral Equipment, NEC” and organised in Israel. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-17. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-31 by RADCOM LTD (CIK 1016838) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 33 A. OPERATING RESULTS 35 B. LIQUIDITY AND CAPITAL RESOURCES 38 C. RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES, ETC. 40 D. TREND INFORMATION 40 E. CRITICAL ACCOUNTING ESTIMATES 40 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 43 A. DIRECTORS AND SENIOR MANAGEMENT 43 B. COMPENSATION 45 C. BOARD PRACTICES 48 D. EMPLOYEES 51 E. SHARE OWNERSHIP 51 F. ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION 51 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 51 A. MAJOR SHAREHOLDERS 51 B. RELATED PARTY TRANSACTIONS 54 C. INTERESTS OF EXPERTS AND COUNSEL 55 ITEM 8. FINANCIAL INFORMATION 55 A. CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION 55 B. SIGNIFICANT CHANGES 55 i ITEM 9.

Financial trend for RADCOM LTD from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $46.05 million (2022-12-31) to $71.49 million (2025-12-31), a change of +55.2%; net income (loss) went from -$2.26 million (2022-12-31) to $11.99 million (2025-12-31), a change of +631.3%; total assets went from $101.00 million (2022-12-31) to $144.97 million (2025-12-31), a change of +43.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1016838, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures RADCOM LTD did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on RADCOM LTD (CIK 1016838) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 253 8-K or 6-K reports in RADCOM LTD’s recent EDGAR index, the 4 listed here run from 2026-08-11 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1016838 is on the EDGAR company page; the latest 20-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 1999-02-18. Insider trades for RADCOM LTD appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Radiant opto-electronics corporation bullish and bearish analyst opinions

What this search refers to. Radiant Opto-Electronics Corporation is a Taiwanese maker of LCD backlight modules listed on the Taiwan Stock Exchange; its disclosures are on MOPS. Official source: mops.twse.com.tw.

No SEC filer could be matched to “Radiant opto-electronics corporation bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Radiant opto-electronics corporation” appears in 1802+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “radiant” (search terms considered: radiant, opto-electronics, corporation).

In the 100 most relevant full-text hits returned for “Radiant opto-electronics corporation”, filings range from 2011-03-31 to 2026-03-25. The filers whose documents mention it most often are ETF Series Solutions (CIK 0001540305) (23 hits); JNL SERIES TRUST (CIK 0000933691) (21 hits); CAUSEWAY CAPITAL MANAGEMENT TRUST (CIK 0001156906) (21 hits); VICTORY PORTFOLIOS (CIK 0000802716) (10 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 60 entities whose registered name contains the word “radiant”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “radiant” 60, “opto-electronics” 0, “corporation” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “radiant” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Radiopharm theranostics limited bullish and bearish analyst opinions

This section ties “Radiopharm theranostics limited bullish and bearish analyst opinions” to Radiopharm Theranostics Ltd (ticker RADX, RDPTF), SEC Central Index Key 1949257, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Australia. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-09-30 by Radiopharm Theranostics Ltd (CIK 1949257) — source document:

Our legal name is Radiopharm Theranostics Limited which was incorporated in Australia in February 2021. Our ordinary shares have been listed on the ASX under the symbol “RAD” since November 2021. In July 2021, we entered into an exclusive license agreement with NanoMab Technologies Limited (“NanoMab”). Under the terms of the agreement, we have the exclusive rights to the technology NanoMab developed, and in particular Anti-HER-2, Anti-TROP-2, Anti-PD-L1 and Anti-PTK7. We have agreed to pay certain upfront license fees and performance-based consideration linked to the achievement of certain value-inflection development milestones and commercial outcomes, as well as net sales-based royalty payments and sublicensing fees. In July 2021, we entered into an exclusive license agreement with TRIMT GmbH (“TRIMT”).

Financial trend for Radiopharm Theranostics Ltd from annual reports, periods 2023-06-30 to 2025-06-30: revenue was tagged only for 2025-06-30 at $3.63 million; net income (loss) went from -$34.61 million (2023-06-30) to -$38.34 million (2025-06-30), a change of -10.8%; total assets went from $72.04 million (2024-06-30) to $86.48 million (2025-06-30), a change of +20.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1949257, tags Assets, ProfitLoss, Revenue; 3 periods shown, dashes mark figures Radiopharm Theranostics Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Radiopharm Theranostics Ltd (CIK 1949257) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-09-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 89 8-K or 6-K reports in Radiopharm Theranostics Ltd’s recent EDGAR index, the 4 listed here run from 2026-09-30 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1949257 is on the EDGAR company page; the latest 20-F there is dated 2026-09-30 and the oldest filing in the recent index dates from 2022-12-16. Insider trades for Radiopharm Theranostics Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Renovorx, inc. bullish and bearish analyst opinions

This section ties “Renovorx, inc. bullish and bearish analyst opinions” to RenovoRx, Inc. (ticker RNXT), SEC Central Index Key 1574094, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a RW dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by RenovoRx, Inc. (CIK 1574094) — source document:

Reimbursement for any approved products may be limited or unavailable, which could make it difficult for us to sell our product candidates profitably. In both domestic and foreign markets, sales of RenovoCath or (if approved) IAG or any of our other drug product candidates, will depend, in part, on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health care programs, commercial insurance and managed health care organizations. These third-party payors decide which drugs will be covered and establish reimbursement levels for those drugs. The 56 containment of health care costs has become a priority of foreign and domestic governments as well as private third-party payors.

Financial trend for RenovoRx, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $43,000 (2024-12-31) to $1.12 million (2025-12-31), a change of +2511.6%; net income (loss) went from -$9.89 million (2022-12-31) to -$11.17 million (2025-12-31), a change of -12.9%; total assets went from $7.26 million (2022-12-31) to $8.10 million (2025-12-31), a change of +11.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1574094, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures RenovoRx, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on RenovoRx, Inc. (CIK 1574094) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-05-14, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 55 8-K or 6-K reports in RenovoRx, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-02 to 2026-08-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1574094 is on the EDGAR company page; the latest 10-K/A there is dated 2026-05-15 and the oldest filing in the recent index dates from 2013-04-10. Insider trades for RenovoRx, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Rhinebeck bancorp, inc. bullish and bearish analyst opinions

This section ties “Rhinebeck bancorp, inc. bullish and bearish analyst opinions” to Rhinebeck Bancorp, Inc. (ticker RBKB), SEC Central Index Key 1751783, an EDGAR registrant classified as “Savings Institutions, Not Federally Chartered” and organised in MD. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-06. Nothing here is a recommendation to trade the security.

Financial trend for Rhinebeck Bancorp, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.83 million (2022-12-31) to $2.98 million (2025-12-31), a change of +5.5%; net income (loss) went from $7.00 million (2022-12-31) to $10.04 million (2025-12-31), a change of +43.6%; total assets went from $1.34 billion (2022-12-31) to $1.30 billion (2025-12-31), a change of -2.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1751783, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures Rhinebeck Bancorp, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Rhinebeck Bancorp, Inc. (CIK 1751783) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-23, and the most recent 10-K annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 72 8-K or 6-K reports in Rhinebeck Bancorp, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 319 recent EDGAR filings, Rhinebeck Bancorp, Inc. most often filed 4 (114), 8-K (72), 3 (25), 10-Q (24). A selection from 2026-07-23 to 2026-08-13:

The full record for CIK 1751783 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2018-09-10. Insider trades for Rhinebeck Bancorp, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Rmg ml sports holdings bullish and bearish analyst opinions

This section ties “Rmg ml sports holdings bullish and bearish analyst opinions” to RMG ML Sports Holdings (ticker SHOT, SHOTR, SHOTU), SEC Central Index Key 2104879, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-12, and this view starts from filings dated on or before 2026-06-09. Nothing here is a recommendation to trade the security.

Financial trend for RMG ML Sports Holdings from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$70,301 (2026-03-31) to -$6.14 million (2026-06-30), a change of -8628.3%; total assets was tagged only for 2026-06-30 at $218.19 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2104879, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures RMG ML Sports Holdings did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on RMG ML Sports Holdings (CIK 2104879) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Other filings. Across its 23 recent EDGAR filings, RMG ML Sports Holdings most often filed 3 (6), 8-K (4), SCHEDULE 13G (2), CORRESP (2). A selection from 2026-06-09 to 2026-06-09:

The full record for CIK 2104879 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-01-29. One example from this record is the SCHEDULE 13G filed 2026-06-16 (document). Insider trades for RMG ML Sports Holdings appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Roadzen, inc. bullish and bearish analyst opinions

This section ties “Roadzen, inc. bullish and bearish analyst opinions” to Roadzen Inc. (ticker RDZN, RDZNW), SEC Central Index Key 1868640, an EDGAR registrant classified as “Insurance Agents, Brokers & Service” and organised in Virgin Islands, British, formerly known as Vahanna Tech Edge Acquisition I Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-06-29 by Roadzen Inc. (CIK 1868640) — source document:

Roadzen is a leading Insurtech company on a mission to transform global auto insurance powered by advanced artificial intelligence (“AI”). At the heart of our mission is our commitment to create transparency, efficiency, and a seamless experience for the millions of end customers who use our products through our insurer, original equipment manufacturer (“OEM”), and fleet (such as trucking, delivery, and commercial fleets) partners. We seek to accomplish this by combining computer vision, telematics and AI with continually updated data sources to provide a more efficient, effective and informed way of building auto insurance products, assessing damages, processing claims and improving driver safety. Insurers and other partners of Roadzen across the world use Roadzen’s technology to launch new auto insurance products, manage risk better and resolve claims faster.

Financial trend for Roadzen Inc. from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from $13.56 million (2023-03-31) to $55.02 million (2026-03-31), a change of +305.8%; net income (loss) went from -$14.02 million (2023-03-31) to -$22.52 million (2026-03-31), a change of -60.6%; total assets went from $15.18 million (2023-03-31) to $52.66 million (2026-03-31), a change of +246.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1868640, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Roadzen Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Roadzen Inc. (CIK 1868640) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-06-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 69 8-K or 6-K reports in Roadzen Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-06 to 2026-09-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1868640 is on the EDGAR company page; the latest 10-K there is dated 2026-06-29 and the oldest filing in the recent index dates from 2021-06-24. Insider trades for Roadzen Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sachem capital corp. bullish and bearish analyst opinions

This section ties “Sachem capital corp. bullish and bearish analyst opinions” to Sachem Capital Corp. (ticker SACH, SACH-PA, SCCD, SCCE, SCCF, SCCG), SEC Central Index Key 1682220, an EDGAR registrant classified as “Real Estate Investment Trusts” and organised in NY. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-13 by Sachem Capital Corp. (CIK 1682220) — source document:

We were organized as a New York corporation in January 2016 under the name HML Capital Corp. On December 15, 2016, we changed our name to Sachem Capital Corp. Prior to February 8, 2017, our business operated as a Connecticut limited liability company under the name Sachem Capital Partners, LLC (“SCP”). On February 9, 2017, we completed our initial public offering (the “IPO”) in which we issued and sold 2.6 million common shares, $0.001 par value per share, (“Common Shares”). We believe that since the consummation of the IPO, we have qualified as a real estate investment trust (“REIT”) and we elected to be taxed as a REIT beginning with our 2017 tax year.

Financial trend for Sachem Capital Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $52.28 million (2022-12-31) to $57.50 million (2024-12-31), a change of +10.0%; net income (loss) went from $20.91 million (2022-12-31) to $6.31 million (2025-12-31), a change of -69.8%; total assets went from $565.66 million (2022-12-31) to $460.05 million (2025-12-31), a change of -18.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1682220, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Sachem Capital Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Sachem Capital Corp. (CIK 1682220) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 144 8-K or 6-K reports in Sachem Capital Corp.’s recent EDGAR index, the 4 listed here run from 2026-06-04 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1682220 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2016-09-09. Insider trades for Sachem Capital Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sanuwave health inc. bullish and bearish analyst opinions

This section ties “Sanuwave health inc. bullish and bearish analyst opinions” to SANUWAVE Health, Inc. (ticker SNWV), SEC Central Index Key 1417663, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in NV, formerly known as RUB MUSIC ENTERPRISES, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-26 by SANUWAVE Health, Inc. (CIK 1417663) — source document:

Sanuwave is a medical device company providing directed energy products into the wound care space. Our mission is to improve patient lives and outcomes by developing and marketing effective, easy to use products to decrease wound burden, lessen healing times, and reduce patient pain. Our focus is regenerative medicine utilizing noninvasive ultrasound to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The Company’s patented and FDA cleared product is the UltraMIST ® system, which is used to treat a variety of acute and chronic wounds. The Company is backed by an intellectual property (“IP”) portfolio of over 60 patents. In the year ended December 31, 2025 , we had total revenues of $44.1 million , a 35% increase from revenues of $32.6 million in the year ended December 31, 2024 . UltraMIST systems and consumables represented approximately 99% of 2025 revenues versus 98% of revenues in 2024.

Financial trend for SANUWAVE Health, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $16.74 million (2022-12-31) to $44.05 million (2025-12-31), a change of +163.1%; net income (loss) went from -$10.29 million (2022-12-31) to $11.81 million (2025-12-31), a change of +214.8%; total assets went from $19.87 million (2022-12-31) to $37.34 million (2025-12-31), a change of +87.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1417663, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SANUWAVE Health, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SANUWAVE Health, Inc. (CIK 1417663) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 211 8-K or 6-K reports in SANUWAVE Health, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-16 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1417663 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2007-12-18. Insider trades for SANUWAVE Health, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Saverone 2014 ltd bullish and bearish analyst opinions

This section ties “Saverone 2014 ltd bullish and bearish analyst opinions” to SaverOne 2014 Ltd. (ticker SVRE, SVREW), SEC Central Index Key 1894693, an EDGAR registrant classified as “Services-Computer Programming Services” and organised in Israel. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a EFFECT dated 2026-10-09. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-27 by SaverOne 2014 Ltd. (CIK 1894693) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 54 A. Operating Results 55 B. Liquidity and Capital Resources 58 C. Research and Development, Patents and Licenses 61 D. Trend Information 61 E. Critical Accounting Estimates 61 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 62 A. Directors and Senior Management 62 B. Compensation 64 C. Board Practices 67 D. Employees 71 E. Share Ownership 71 F. Disclosure of a registrant’s action to recover erroneously awarded compensation 72 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 72 A. Major Shareholders 72 B. Related Party Transactions 74 C. Interests of Experts and Counsel 75 ITEM 8. FINANCIAL INFORMATION 75 A. Statements and Other Financial Information 75 B. Significant Changes 75 ITEM 9.

Financial trend for SaverOne 2014 Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 1,193,000 ILS (2022-12-31) to 1,016,000 ILS (2025-12-31), a change of -14.8%; net income (loss) went from -24,962,000 ILS (2022-12-31) to -29,443,000 ILS (2025-12-31), a change of -18.0%; total assets went from 34,435,000 ILS (2022-12-31) to 20,923,000 ILS (2025-12-31), a change of -39.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1894693, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures SaverOne 2014 Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SaverOne 2014 Ltd. (CIK 1894693) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 171 8-K or 6-K reports in SaverOne 2014 Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-18 to 2026-10-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1894693 is on the EDGAR company page; the latest 20-F there is dated 2026-03-27 and the oldest filing in the recent index dates from 2021-12-28. Insider trades for SaverOne 2014 Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Scisparc ltd. bullish and bearish analyst opinions

This section ties “Scisparc ltd. bullish and bearish analyst opinions” to SciSparc Ltd. (ticker SPRC), SEC Central Index Key 1611746, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Israel, formerly known as SciSparc Ltd./ADR. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-29 by SciSparc Ltd. (CIK 1611746) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 90 A. Operating Results 90 B. Liquidity and Capital Resources 94 C. Research and development, patents and licenses, etc. 99 D. Trend information 99 E. Critical Accounting Estimates 99 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 100 A. Directors and Senior Management 100 B. Compensation 102 C. Board Practices 104 D. Employees 117 E. Share Ownership 117 F. Action to Recover Erroneously Awarded Compensation 117 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 117 A. Major Shareholders 117 B. Related Party Transactions 120 C. Interests of Experts and Counsel 122 ITEM 8. FINANCIAL INFORMATION 122 A. Consolidated Statements and Other Financial Information 122 B. Significant Changes 123 ITEM 9.

Financial trend for SciSparc Ltd. from annual reports, periods 2020-12-31 to 2024-12-31: revenue went from $1.35 million (2022-12-31) to $1.31 million (2024-12-31), a change of -3.0%; net income (loss) was tagged only for 2020-12-31 at -$3.54 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1611746, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures SciSparc Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SciSparc Ltd. (CIK 1611746) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 329 8-K or 6-K reports in SciSparc Ltd.’s recent EDGAR index, the 4 listed here run from 2026-10-07 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1611746 is on the EDGAR company page; the latest 20-F there is dated 2026-04-29 and the oldest filing in the recent index dates from 2014-07-18. Insider trades for SciSparc Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Seacor marine holdings inc. bullish and bearish analyst opinions

This section ties “Seacor marine holdings inc. bullish and bearish analyst opinions” to SEACOR Marine Holdings Inc. (ticker SMHI), SEC Central Index Key 1690334, an EDGAR registrant classified as “Deep Sea Foreign Transportation of Freight” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-04. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-25 by SEACOR Marine Holdings Inc. (CIK 1690334) — source document:

Gene ral Unless the context indicates otherwise, the terms “we,” “our,” “ours,” “us,” “its” and the “Company” refer to SEACOR Marine Holdings Inc. and its consolidated subsidiaries. “SEACOR Marine” refers to SEACOR Marine Holdings Inc., incorporated in 2014 in Delaware, without its subsidiaries. “Common Stock” refers to the common stock, par value $0.01 per share, of SEACOR Marine. The Company’s fiscal year ends on December 31 of each year. SEACOR Marine’s principal executive office is located at 12121 Wickchester Lane, Suite 500, Houston, Texas 77079, and its telephone number is (346) 980-1700. SEACOR Marine’s website address is www.seacormarine.com . Any reference to SEACOR Marine’s website is not intended to incorporate the information on the website into this Annual Report on Form 10-K. The Company’s corporate governance documents, including SEACOR Marine’s board of directors’ (“Board of Directors”) Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee charters as well as the Company’s Corporate Governance Guidelines, Code of Ethics and Insider Trading and Tipping Procedures and Guidelines (“Insider Trading Policy”) are available, free of charge, on SEACOR Marine’s website or in print for stockholders who request a copy.

Financial trend for SEACOR Marine Holdings Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$71.65 million (2022-12-31) to -$78.12 million (2024-12-31), a change of -9.0%; total assets went from $815.37 million (2022-12-31) to $660.60 million (2025-12-31), a change of -19.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1690334, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SEACOR Marine Holdings Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SEACOR Marine Holdings Inc. (CIK 1690334) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-29, and the most recent 10-K annual report was filed 2026-02-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 117 8-K or 6-K reports in SEACOR Marine Holdings Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-29 to 2026-07-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1690334 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2016-12-13. Insider trades for SEACOR Marine Holdings Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sensient technologies corporation bullish and bearish analyst opinions

This section ties “Sensient technologies corporation bullish and bearish analyst opinions” to SENSIENT TECHNOLOGIES CORP (ticker SXT), SEC Central Index Key 310142, an EDGAR registrant classified as “Industrial Organic Chemicals” and organised in WI, formerly known as UNIVERSAL FOODS CORP. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-01. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-13 by SENSIENT TECHNOLOGIES CORP (CIK 310142) — source document:

Mine Safety Disclosure 21 Information About Our Executive Officers 22 PART II 23 Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 23 Item 6. [Reserved] 23 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 7A. Quantitative and Qualitative Disclosures about Market Risk 30 Item 8. Financial Statements and Supplementary Data 31 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 57 Item 9A. Controls and Procedures 57 Item 9B. Other Information 59 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 59 PART III 60 Item 10. Directors, Executive Officers of the Registrant, and Corporate Governance 60 Item 11.

Financial trend for SENSIENT TECHNOLOGIES CORP from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $140.89 million (2022-12-31) to $134.49 million (2025-12-31), a change of -4.5%; total assets went from $1.98 billion (2022-12-31) to $2.24 billion (2025-12-31), a change of +13.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 310142, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SENSIENT TECHNOLOGIES CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SENSIENT TECHNOLOGIES CORP (CIK 310142) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-24, and the most recent 10-K annual report was filed 2026-02-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 138 8-K or 6-K reports in SENSIENT TECHNOLOGIES CORP’s recent EDGAR index, the 4 listed here run from 2026-04-28 to 2026-09-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 310142 is on the EDGAR company page; the latest 10-K there is dated 2026-02-13 and the oldest filing in the recent index dates from 2014-03-13. Insider trades for SENSIENT TECHNOLOGIES CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sera prognostics, inc. bullish and bearish analyst opinions

This section ties “Sera prognostics, inc. bullish and bearish analyst opinions” to SERA PROGNOSTICS, INC. (ticker SERA), SEC Central Index Key 1534969, an EDGAR registrant classified as “Services-Medical Laboratories” and organised in DE, formerly known as SERA PROGNOSTICS, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-13. Nothing here is a recommendation to trade the security.

Financial trend for SERA PROGNOSTICS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $306,000 (2023-12-31) to $81,000 (2025-12-31), a change of -73.5%; net income (loss) went from -$44.19 million (2022-12-31) to -$31.93 million (2025-12-31), a change of +27.7%; total assets went from $116.33 million (2022-12-31) to $101.93 million (2025-12-31), a change of -12.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1534969, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SERA PROGNOSTICS, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SERA PROGNOSTICS, INC. (CIK 1534969) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-03-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 52 8-K or 6-K reports in SERA PROGNOSTICS, INC.’s recent EDGAR index, the 4 listed here run from 2026-06-04 to 2026-08-19, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 658 recent EDGAR filings, SERA PROGNOSTICS, INC. most often filed 4 (283), 144 (177), 8-K (52), 3 (28). A selection from 2026-09-11 to 2026-10-13:

The full record for CIK 1534969 is on the EDGAR company page; the latest 10-K there is dated 2026-03-18 and the oldest filing in the recent index dates from 2011-11-21. Insider trades for SERA PROGNOSTICS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Seres therapeutics, inc. bullish and bearish analyst opinions

This section ties “Seres therapeutics, inc. bullish and bearish analyst opinions” to Seres Therapeutics, Inc. (ticker MCRB), SEC Central Index Key 1609809, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as Seres Therapeutics, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a EFFECT dated 2026-08-21. Nothing here is a recommendation to trade the security.

Financial trend for Seres Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $7.13 million (2022-12-31) to $789,000 (2025-12-31), a change of -88.9%; net income (loss) went from -$250.16 million (2022-12-31) to $5.70 million (2025-12-31), a change of +102.3%; total assets went from $348.78 million (2022-12-31) to $138.19 million (2025-12-31), a change of -60.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1609809, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Seres Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Seres Therapeutics, Inc. (CIK 1609809) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 120 8-K or 6-K reports in Seres Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-08 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 721 recent EDGAR filings, Seres Therapeutics, Inc. most often filed 4 (337), 8-K (120), SC 13G/A (39), 3 (36). A selection from 2026-08-18 to 2026-08-21:

The full record for CIK 1609809 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2014-06-09. Insider trades for Seres Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Silverbox corp iv bullish and bearish analyst opinions

This section ties “Silverbox corp iv bullish and bearish analyst opinions” to SilverBox Corp IV (ticker SBXDF, SBXUF, SBXWF), SEC Central Index Key 2015947, an EDGAR registrant classified as “Blank Checks” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 25-NSE dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-19 by SilverBox Corp IV (CIK 2015947) — source document:

We are a newly organized blank check company incorporated as a Cayman Islands exempted company on April 16, 2024 for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to as our initial business combination. The Company has not commenced any operations nor generated any revenues to date. All activity for the period from April 16, 2024 (inception) through December 31, 2024 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”) described below, and since the Initial Public Offering to its search for an initial business combination. We are also an emerging growth company and, as such, we are subject to all of the risks associated with emerging growth companies.

Financial trend for SilverBox Corp IV from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $5.72 million; total assets went from $205.66 million (2024-12-31) to $213.49 million (2025-12-31), a change of +3.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2015947, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures SilverBox Corp IV did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SilverBox Corp IV (CIK 2015947) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 16 8-K or 6-K reports in SilverBox Corp IV’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-09-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2015947 is on the EDGAR company page; the latest 10-K there is dated 2026-03-19 and the oldest filing in the recent index dates from 2024-06-18. Insider trades for SilverBox Corp IV appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Smartbird, inc bullish and bearish analyst opinions

This section ties “Smartbird, inc bullish and bearish analyst opinions” to Smartbird, Inc. (ticker BIRD), SEC Central Index Key 1653909, an EDGAR registrant classified as “Services-Computer Processing & Data Preparation” and organised in an unstated jurisdiction, formerly known as Allbirds, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Smartbird, Inc. (CIK 1653909) — source document:

Allbirds is a global lifestyle brand that innovates with naturally derived materials to make better footwear and apparel products in a better way, while treading lighter on our planet. We began our journey in 2015 with three fundamental beliefs about the emerging generation of consumers: first, these consumers recognize that climate change is an existential threat to the human race; second, these consumers connect their purchase decisions with their impact on the planet, demanding more from businesses; and third, these consumers do not want to compromise between looking good, feeling good, and doing good. We became a public benefit corporation, or PBC, under Delaware law and earned our B Corporation, or B Corp, certification in 2016, codifying how we take into account the impact our actions have on all of our stakeholders, including the environment, our flock of employees, communities, consumers, and investors.

Financial trend for Smartbird, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $297.77 million (2022-12-31) to $152.47 million (2025-12-31), a change of -48.8%; net income (loss) went from -$101.35 million (2022-12-31) to -$77.28 million (2025-12-31), a change of +23.7%; total assets went from $462.36 million (2022-12-31) to $109.42 million (2025-12-31), a change of -76.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1653909, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures Smartbird, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Smartbird, Inc. (CIK 1653909) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-04-21, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 51 8-K or 6-K reports in Smartbird, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-29 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1653909 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2016-03-11. Insider trades for Smartbird, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sonida senior living, inc. bullish and bearish analyst opinions

This section ties “Sonida senior living, inc. bullish and bearish analyst opinions” to SONIDA SENIOR LIVING, INC. (ticker SNDA), SEC Central Index Key 1043000, an EDGAR registrant classified as “Services-Nursing & Personal Care Facilities” and organised in DE, formerly known as CAPITAL SENIOR LIVING CORP. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-12 by SONIDA SENIOR LIVING, INC. (CIK 1043000) — source document:

Sonida Senior Living, Inc., a Delaware corporation (together with its subsidiaries, “we,” “us,” “our,” “Sonida,” or the “Company”), is a leading owner, operator and investor in senior housing communities in the United States in terms of resident capacity. The Company and its predecessors have provided senior housing since 1990. As of December 31, 2025, the Company owned, managed, or invested in 96 senior housing communities in 20 states with an aggregate capacity of approximately 10,150 residents, including 84 owned senior housing communities (inclusive of four owned through joint venture investments in consolidated entities and four owned through a joint venture investment in an unconsolidated entity) and 12 communities that the Company managed on behalf of a third-party.

Financial trend for SONIDA SENIOR LIVING, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $238.43 million (2022-12-31) to $381.14 million (2025-12-31), a change of +59.9%; net income (loss) went from -$54.40 million (2022-12-31) to -$70.78 million (2025-12-31), a change of -30.1%; total assets went from $661.27 million (2022-12-31) to $844.85 million (2025-12-31), a change of +27.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1043000, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SONIDA SENIOR LIVING, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on SONIDA SENIOR LIVING, INC. (CIK 1043000) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 167 8-K or 6-K reports in SONIDA SENIOR LIVING, INC.’s recent EDGAR index, the 4 listed here run from 2026-08-10 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1043000 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2012-11-08. Insider trades for SONIDA SENIOR LIVING, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Spartacus acquisition corp. ii bullish and bearish analyst opinions

This section ties “Spartacus acquisition corp. ii bullish and bearish analyst opinions” to Spartacus Acquisition Corp. II (ticker TMTS, TMTSU, TMTSW), SEC Central Index Key 2097364, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14, and this view starts from filings dated on or before 2026-02-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by Spartacus Acquisition Corp. II (CIK 2097364) (passage 2, continuing from the earlier excerpt) — source document:

Initial Public Offering Our IPO Registration Statement became effective on January 30, 2026. On February 12, 2026 we consummated our Initial Public Offering of 23,000,000 Public Units, including 3,000,000 Option Units issued pursuant to the full exercise of the Over-Allotment Option. Each Public Unit consists of one Public Share and one-third of one Public Warrant, with each whole Public Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share. The Public Units were sold at a price of $10.00 per Public Unit, generating gross proceeds to our Company of $230,000,000. Simultaneously with the closing of the Initial Public Offering and pursuant to the Private Placement Warrants Purchase Agreement, we completed the private sale of an aggregate of 4,125,000 Private Placement Warrants to our Sponsor in the Private Placement at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to our Company of $4,125,000.

Financial trend for Spartacus Acquisition Corp. II from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $899,846 (2026-03-31) to $1.93 million (2026-06-30), a change of +114.3%; total assets went from $232.14 million (2026-03-31) to $234.07 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2097364, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Spartacus Acquisition Corp. II did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Spartacus Acquisition Corp. II (CIK 2097364) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Spartacus Acquisition Corp. II — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-02-11.

Other filings. Across its 28 recent EDGAR filings, Spartacus Acquisition Corp. II most often filed 3 (7), SCHEDULE 13G (5), 8-K (3), 10-Q (2). A selection from 2026-02-11 to 2026-05-12:

The full record for CIK 2097364 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2025-12-23. One example from this record is the SCHEDULE 13G filed 2026-05-13 (document). Insider trades for Spartacus Acquisition Corp. II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Standex international corporation bullish and bearish analyst opinions

This section ties “Standex international corporation bullish and bearish analyst opinions” to STANDEX INTERNATIONAL CORP/DE/ (ticker SXI), SEC Central Index Key 310354, an EDGAR registrant classified as “Refrigeration & Service Industry Machinery” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-08-14 by STANDEX INTERNATIONAL CORP/DE/ (CIK 310354) — source document:

Standex International Corporation and subsidiaries ("we," "us," "our," the "Company" and "Standex") is a diversified industrial manufacturer with leading positions in a variety of products and services that are used in diverse commercial and industrial markets. Headquartered in Salem, New Hampshire, we have four operating and reportable segments: Electronics, Aerospace and Defense (A&D), Scientific and Engraving & Hydraulics. Our businesses work in close partnership with our customers to deliver custom solutions or engineered components that solve their unique and specific needs, an approach we call "Customer Intimacy." Standex was incorporated in 1975 and is the successor of a corporation organized in 1955. We have paid dividends each quarter since Standex became a public corporation in November 1964.

Financial trend for STANDEX INTERNATIONAL CORP/DE/ from annual reports, periods 2023-06-30 to 2026-06-30: net income (loss) went from $138.99 million (2023-06-30) to $104.63 million (2026-06-30), a change of -24.7%; total assets went from $1.02 billion (2023-06-30) to $1.59 billion (2026-06-30), a change of +54.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 310354, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures STANDEX INTERNATIONAL CORP/DE/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on STANDEX INTERNATIONAL CORP/DE/ (CIK 310354) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-31, and the most recent 10-K annual report was filed 2026-08-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 104 8-K or 6-K reports in STANDEX INTERNATIONAL CORP/DE/’s recent EDGAR index, the 4 listed here run from 2026-07-02 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 310354 is on the EDGAR company page; the latest 10-K there is dated 2026-08-14 and the oldest filing in the recent index dates from 2014-05-02. Insider trades for STANDEX INTERNATIONAL CORP/DE/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sun hung kai properties limited bullish and bearish analyst opinions

The legal-form ending in “Sun hung kai properties limited” is the clue: “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. A company of that kind reports in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), so the place to read its annual report and announcements is that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) — www.hkexnews.hk.

No SEC filer could be matched to “Sun hung kai properties limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Sun hung kai properties limited” appears in 4258+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “sun” (search terms considered: sun, hung, kai, properties).

A broader EDGAR full-text search for the shorter phrase “Sun hung kai” finds 10000+ filing documents; among the top 100, the filers mentioning it most are GuideStone Funds (CIK 0001131013) (25); SUN HUNG KAI & CO LTD (CIK 0000764715) (20); Vicarious Surgical Inc. (RBOT, RBOT-WT) (CIK 0001812173) (10). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Sun hung kai properties limited”, filings range from 2005-04-29 to 2026-10-23. The filers whose documents mention it most often are JNL SERIES TRUST (CIK 0000933691) (12 hits); Advisors' Inner Circle Fund III (CIK 0001593547) (10 hits); FEDERATED WORLD INVESTMENT SERIES INC (CIK 0000918199) (8 hits); Principal Real Estate Income Fund (PGZ) (CIK 0001557523) (4 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 195+ entities whose registered name contains the word “sun”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “sun” 476, “hung” 104, “kai” 129, “properties” 482. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “sun” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Syn-tech chem. & pharm. co., ltd. bullish and bearish analyst opinions

Read from its name, “Syn-tech chem. & pharm. co., ltd.” is a China, Taiwan, Korea or Japan entity — “Co., Ltd.” is the English rendering used by limited companies across East Asia. Its accounts and exchange notices are published through the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Syn-tech chem. & pharm. co., ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Syn-tech chem. & pharm. co., ltd.” appears in 659+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “syn-tech” (search terms considered: syn-tech, chem, pharm).

A broader EDGAR full-text search for the shorter phrase “Syn-tech chem. pharm.” finds 659+ filing documents; among the top 100, the filers mentioning it most are DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (62); Dimensional ETF Trust (CIK 0001816125) (31); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (4). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Syn-tech chem. & pharm. co., ltd.”, filings range from 2023-09-27 to 2025-09-25. The filers whose documents mention it most often are DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (62 hits); Dimensional ETF Trust (CIK 0001816125) (31 hits); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (4 hits); DFA INVESTMENT TRUST CO (CIK 0000896162) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 0 entities whose registered name contains the word “syn-tech”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “syn-tech” 0, “chem” 28, “pharm” 22. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “syn-tech” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Tak lee machinery holdings limited bullish and bearish analyst opinions

“Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. The name “Tak lee machinery holdings limited” therefore points to a company organised in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), and its official disclosures are on that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk), not on EDGAR.

No SEC filer could be matched to “Tak lee machinery holdings limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Tak lee machinery holdings limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “tak” (search terms considered: tak, lee, machinery).

Even the shorter phrase “Tak lee machinery” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (tak, lee, machinery) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 40 entities whose registered name contains the word “tak”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “tak” 40, “lee” 498, “machinery” 36. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “tak”: BLONDEL SO KING TAK (CIK 1638399), CHEN YEUNG TAK (CIK 2126138), CHENG TAK YIU (CIK 1923127); containing “lee”: 17TH & JENNIE LEE, LLC (CIK 1864854), 2021 LEE FAMILY GST TRUST (CIK 1969959), ADAMS LAURA LEE (CIK 1891764); containing “machinery”: BEIJING BEIKE MACHINERY ELECTRONIC MATERIALS HIGHTECH CORP (CIK 1316298), BEIJING BEIKE MACHINERY ELECTRONICS MATERIALS HIGHTECH CORP (CIK 1258229), BEIJING YSKN MACHINERY & ELECTRONIC EQUIPMENT CO., LTD. (CIK 1433290). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “tak” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Tantech holdings ltd bullish and bearish analyst opinions

This section ties “Tantech holdings ltd bullish and bearish analyst opinions” to TANTECH HOLDINGS LTD (ticker TANH), SEC Central Index Key 1588084, an EDGAR registrant classified as “Industrial Organic Chemicals” and organised in Virgin Islands, British. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-05-14 by TANTECH HOLDINGS LTD (CIK 1588084) — source document:

Tantech Bamboo was established in October 2002 under the trading name “Lishui Zhonglin High Tech Co., Ltd.” by its incumbent owner. Lishui Forasen Food Co. Ltd. was established in January 1998. In April 2003, it changed its name to Lishui Forasen Green Industry Group, later renamed Forasen Group Co. Ltd. (“Forasen Group”). In May 2003, 60% of THL’s shares were acquired by the Forasen Group. A second subsidiary, Zhejiang Tantech Bamboo Charcoal Co., Ltd. (“Tantech Charcoal”), was acquired in September 2006 to manage the Forasen Group’s export business. In September 2008 a third subsidiary, Zhejiang Tantech Energy Technology Co., Ltd. (“Tantech Energy”), was established to research and develop bamboo charcoals application as a carbon component for EDLCs.

Financial trend for TANTECH HOLDINGS LTD from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $52.97 million (2022-12-31) to $38.36 million (2025-12-31), a change of -27.6%; net income (loss) went from $2.59 million (2022-12-31) to -$31.02 million (2025-12-31), a change of -1299.6%; total assets went from $134.13 million (2022-12-31) to $123.97 million (2025-12-31), a change of -7.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1588084, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures TANTECH HOLDINGS LTD did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TANTECH HOLDINGS LTD (CIK 1588084) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-05-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 132 8-K or 6-K reports in TANTECH HOLDINGS LTD’s recent EDGAR index, the 4 listed here run from 2026-08-19 to 2026-10-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1588084 is on the EDGAR company page; the latest 20-F there is dated 2026-05-14 and the oldest filing in the recent index dates from 2013-09-30. Insider trades for TANTECH HOLDINGS LTD appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tela bio, inc. bullish and bearish analyst opinions

This section ties “Tela bio, inc. bullish and bearish analyst opinions” to TELA Bio, Inc. (ticker TELA), SEC Central Index Key 1561921, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-25 by TELA Bio, Inc. (CIK 1561921) — source document:

We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide. We are dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements. We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market.

Financial trend for TELA Bio, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $41.42 million (2022-12-31) to $80.28 million (2025-12-31), a change of +93.8%; net income (loss) went from -$44.30 million (2022-12-31) to -$38.83 million (2025-12-31), a change of +12.3%; total assets went from $67.86 million (2022-12-31) to $81.42 million (2025-12-31), a change of +20.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1561921, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures TELA Bio, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TELA Bio, Inc. (CIK 1561921) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 93 8-K or 6-K reports in TELA Bio, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-29 to 2026-10-08, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1561921 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2012-12-06. Insider trades for TELA Bio, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Telo genomics corp. bullish and bearish analyst opinions

This section ties “Telo genomics corp. bullish and bearish analyst opinions” to Telo Genomics Corp. (ticker none listed), SEC Central Index Key 1872138, an EDGAR registrant classified as “no SIC description” and organised in Canada (Federal Level). The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a D dated 2026-04-24. Nothing here is a recommendation to trade the security.

Analyst ratings, price targets and “bullish” or “bearish” calls on Telo Genomics Corp. (CIK 1872138) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

What kind of filer this is matters for “Telo genomics corp. bullish and bearish analyst opinions”: Telo Genomics Corp.’s EDGAR record from 2021-07-15 to 2026-04-24 consists only of Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it; as a company organised in Canada (Federal Level), its own reports would be with the Canadian Securities Administrators’ SEDAR+ system (www.sedarplus.ca).

Other filings. Across its 3 recent EDGAR filings, Telo Genomics Corp. most often filed D (3). A selection from 2021-07-15 to 2026-04-24:

The full record for CIK 1872138 is on the EDGAR company page and the oldest filing in the recent index dates from 2021-07-15. Insider trades for Telo Genomics Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

The marygold companies, inc. bullish and bearish analyst opinions

This section ties “The marygold companies, inc. bullish and bearish analyst opinions” to Marygold Companies, Inc. (ticker MGLD), SEC Central Index Key 1005101, an EDGAR registrant classified as “Finance Services” and organised in NV, formerly known as CONCIERGE TECHNOLOGIES INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-30. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-09-18 by Marygold Companies, Inc. (CIK 1005101) — source document:

The Marygold Companies, Inc., a Nevada corporation (together with its subsidiaries, “we,” “us,” “our,” “Company,” or “The Marygold Companies”) is a holding company which operates through its wholly owned subsidiaries on a multinational scale that is focused upon financial services, exchange traded funds management and certain other business activities listed below: ● U.S. Fund Management - USCF Investments, Inc., a Delaware corporation (“USCF Investments”), with corporate headquarters in Walnut Creek, California and its wholly owned subsidiaries, which provide fund management services to exchange traded fund and exchange traded products (“ETFs”): ○ United States Commodity Funds, LLC, a Delaware limited liability company (“USCF LLC”), and ○ USCF Advisers, LLC, a Delaware limited liability company (“USCF Advisers”).

Financial trend for Marygold Companies, Inc. from annual reports, periods 2023-06-30 to 2026-06-30: revenue was tagged only for 2023-06-30 at $34.88 million; net income (loss) went from $1.17 million (2023-06-30) to -$4.37 million (2026-06-30), a change of -475.2%; total assets went from $35.28 million (2023-06-30) to $23.98 million (2026-06-30), a change of -32.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1005101, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Marygold Companies, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Marygold Companies, Inc. (CIK 1005101) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-21, and the most recent 10-K annual report was filed 2026-09-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 75 8-K or 6-K reports in Marygold Companies, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-21 to 2026-09-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1005101 is on the EDGAR company page; the latest 10-K there is dated 2026-09-18 and the oldest filing in the recent index dates from 2000-03-10. Insider trades for Marygold Companies, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Townsquare media, inc. bullish and bearish analyst opinions

This section ties “Townsquare media, inc. bullish and bearish analyst opinions” to Townsquare Media, Inc. (ticker TSQ), SEC Central Index Key 1499832, an EDGAR registrant classified as “Radio Broadcasting Stations” and organised in DE, formerly known as Townsquare Media, LLC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-16 by Townsquare Media, Inc. (CIK 1499832) — source document:

Description of Business Townsquare is a community-focused digital and broadcast media and digital marketing solutions company principally focused outside the top 50 markets in the U.S. Townsquare Ignite, our robust digital advertising division, specializes in helping businesses of all sizes connect with their target audience through data-driven, results based strategies, by utilizing a) our proprietary digital programmatic advertising technology stack with an in-house demand and data management platform and b) our owned and operated portfolio of more than 400 local news and entertainment websites and mobile apps along with a network of leading national music and entertainment brands, collecting valuable first party data. Townsquare Interactive, our subscription digital marketing services business, partners with SMBs to help manage their digital presence by providing a SAAS business management platform, website design, creation and hosting, search engine optimization and other digital services.

Financial trend for Townsquare Media, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $463.08 million (2022-12-31) to $427.38 million (2025-12-31), a change of -7.7%; net income (loss) went from $12.34 million (2022-12-31) to -$11.52 million (2025-12-31), a change of -193.3%; total assets went from $744.52 million (2022-12-31) to $528.62 million (2025-12-31), a change of -29.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1499832, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Townsquare Media, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Townsquare Media, Inc. (CIK 1499832) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 109 8-K or 6-K reports in Townsquare Media, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-16 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1499832 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2010-08-26. Insider trades for Townsquare Media, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Tribeca strategic acquisition corp. bullish and bearish analyst opinions

This section ties “Tribeca strategic acquisition corp. bullish and bearish analyst opinions” to Tribeca Strategic Acquisition Corp. (ticker BID, BIDWR, BIDWU), SEC Central Index Key 2094919, an EDGAR registrant classified as “Blank Checks” and organised in an unstated jurisdiction. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-07, and this view starts from filings dated on or before 2026-06-01. Nothing here is a recommendation to trade the security.

Financial trend for Tribeca Strategic Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$63,610 (2026-03-31) to $243,475 (2026-06-30), a change of +482.8%; total assets was tagged only for 2026-06-30 at $141.71 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2094919, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Tribeca Strategic Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Tribeca Strategic Acquisition Corp. (CIK 2094919) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Tribeca Strategic Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 6 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-06-01.

Other filings. Across its 24 recent EDGAR filings, Tribeca Strategic Acquisition Corp. most often filed 3 (5), SCHEDULE 13G (4), S-1/A (4), 8-K (3). A selection from 2026-05-28 to 2026-06-05:

The full record for CIK 2094919 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-11-10. One example from this record is the 8-K filed 2026-07-17 (document). Insider trades for Tribeca Strategic Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Trisalus life sciences, inc. bullish and bearish analyst opinions

This section ties “Trisalus life sciences, inc. bullish and bearish analyst opinions” to TriSalus Life Sciences, Inc. (ticker TLSI, TLSIW), SEC Central Index Key 1826667, an EDGAR registrant classified as “Surgical & Medical Instruments & Apparatus” and organised in DE, formerly known as MedTech Acquisition Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-05 by TriSalus Life Sciences, Inc. (CIK 1826667) — source document:

Unless the context indicates otherwise, references in this Annual Report to the “Company,” “TriSalus,” “we,” “us,” “our” and similar terms refer to TriSalus Life Sciences, Inc. (f/k/a MedTech Acquisition Corp.), a Delaware corporation and its consolidated subsidiaries. Overview We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist, for a range of different therapeutic and technology applications. Our ultimate goal is to transform the treatment paradigm for patients battling solid tumors. We have developed an innovative technology designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) off target delivery.

Financial trend for TriSalus Life Sciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $12.40 million (2022-12-31) to $45.15 million (2025-12-31), a change of +264.2%; net income (loss) went from -$47.19 million (2022-12-31) to -$39.23 million (2025-12-31), a change of +16.9%; total assets went from $22.00 million (2022-12-31) to $35.33 million (2025-12-31), a change of +60.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1826667, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures TriSalus Life Sciences, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on TriSalus Life Sciences, Inc. (CIK 1826667) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 87 8-K or 6-K reports in TriSalus Life Sciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-09-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1826667 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2020-10-29. Insider trades for TriSalus Life Sciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET